Sabirnetug fails to meet primary endpoint in Phase 2 Alzheimer's trial
Acumen Pharmaceuticals reported that sabirnetug failed to meet its primary cognitive endpoint in a Phase 2 trial for Alzheimer's disease, leading the company to halt development of the drug and focus on strategic options and cash conservation.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed